Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 1.46 — trading near book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -5.6%
- Revenue growing at 6% annually
BAXTER INTERNATIONAL INC (BAX) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $9.0 billion . Key value metrics: P/B ratio 1.46, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
BAXTER INTERNATIONAL INC — Fundamental Analysis Summary
On financial health, BAX shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -5.6% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.54.
StockPik's composite Value Score for BAX is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BAX reports a moderate gross margin of 34.1% (sector average: 33.5%) and a modest operating margin of 5.2%.
BAX shows revenue growing at 6% year-over-year, with earnings declining at 47%.
BAX pays a solid dividend yield of 4.6%.